<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692012</url>
  </required_header>
  <id_info>
    <org_study_id>EHPristina</org_study_id>
    <nct_id>NCT04692012</nct_id>
  </id_info>
  <brief_title>Treatment of Residual Hypermetropic Refraction on Pseudophakic Patients Using Allogenic Fresh Myopic Lenticule</brief_title>
  <acronym>ReLex-Smile</acronym>
  <official_title>Successful Treatment of Residual Hypermetropic Refraction on Pseudophakic Patients Using Allogenic Fresh Myopic Lenticule Implantation With ReLex-Smile Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Hospital Pristina Kosovo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye Hospital Pristina Kosovo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The residual hypermetropic refraction on pseudophakic(Trifocal IOL) patients is difficult to&#xD;
      treat surgically. In addition, there are not many suitable options to offer such patients&#xD;
      presenting with this condition.&#xD;
&#xD;
      Two current common surgeries to treat residual hyperopic refraction are refractive lens&#xD;
      exchange (RLE) and excimer laser ablation (LASIK or PRK).&#xD;
&#xD;
      Laser procedures: Photorefractive keratectomy (PRK); Laser assisted in situ keratomileusis&#xD;
      (LASIK); Risks of LASIK include abnormalities of the corneal flap, epithelial ingrowth,&#xD;
      corneal ectasia, refractive surprises, irregular astigmatism, decentration, visual&#xD;
      aberrations, a loss of BCVA, infectious keratitis, symptoms, and diffuse lamellar keratitis.&#xD;
&#xD;
      Refractive lens exchange (RLE); The risks of RLE are similar to those of cataract surgery and&#xD;
      include endophthalmitis, a loss of accommodation, vitreous loss with posterior capsular&#xD;
      rupture, and retinal detachment.&#xD;
&#xD;
      The method used at the EYE Hospital Pristina using fresh lenticule implantation by&#xD;
      ReLex-SMILE is safe and effective method, since there is no flap this prevents invasive&#xD;
      damage to the anterior surface of the cornea contrary to the LASIK where flap is present&#xD;
      posing risk for epithelial ingrowth.&#xD;
&#xD;
      Before SMILE,YAG-laser capsulotomy should be performed on all patients, regardless of&#xD;
      posterior capsule ossification, in pseudophakic patients with residual refraction. When the&#xD;
      YAG-laser is applied after the SMILE,there will be a diopter change.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to investigate the effect of fresh myopic corneal lenticule implantation as&#xD;
      allogenic implant that will be taken from myopic patients to implant on pseudophakic&#xD;
      patients(Trifocal IOL) with residual hypermetropic refraction(over +0.50Dsph) using VisuMax&#xD;
      Femtosecond laser - Smile module surgery with primary objective to assess (increase) visual&#xD;
      acuity . In pseudophakic patients with hyperopic astigmatism residual refraction, corneal&#xD;
      topography-guided intrastromal fresh lenticule implantation should be performed and the&#xD;
      lenticule was placed according to the low K value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>pseudophakic group hyperopic group myopic group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>pseudophakic (Trifocal IOL) group 492 patients-246 eyes residual hyperopic group 34 patients-38 eyes</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>increasing of visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>using fresh myopic corneal lenticule for treatment of residual hypermetropic refraction on pseudophakic patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pseudophakia</condition>
  <condition>Hypermetropia</condition>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>FRESH CORNEAL LENTICULE IMPLANTATION</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The aim of this study is to investigate the effect of fresh corneal myopic lenticule implantation as allogenic implant that will be taken from myopic patients to implant on pseudophakic patients with residual hypermetropic refraction using VisuMax Femtosecond Laser-Smile module surgery with primary objective to assess(increase) visual acuity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION</intervention_name>
    <description>VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.</description>
    <arm_group_label>FRESH CORNEAL LENTICULE IMPLANTATION</arm_group_label>
    <other_name>Relex smile surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  residual hypermetropic refraction on pseudophakic patients&#xD;
&#xD;
          -  low visual acuity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active anterior segment pathologic features,&#xD;
&#xD;
          -  previous corneal or anterior segment surgery,&#xD;
&#xD;
          -  glaucoma,&#xD;
&#xD;
          -  retinal detachment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eye Hospital Pristina</name>
      <address>
        <city>Pristina</city>
        <zip>10000</zip>
        <country>Kosovo</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kosovo</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye Hospital Pristina Kosovo</investigator_affiliation>
    <investigator_full_name>Dr. Faruk Semiz</investigator_full_name>
    <investigator_title>Head of Ophthalmology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
    <mesh_term>Pseudophakia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

